Company: Savient Pharmaceuticals, Inc.
Treatment for: Gout
Krystexxa (pegloticase) is a bio-uricolytic agent in late-stage development for treatment-failure gout to control hyperuricemia and to manage the signs and symptoms of gout.
Treatment for: Insomnia
Ciltyri (eplivanserin) is a serotonin type 2 A receptor antagonist under review as a potential treatment for patients with chronic insomnia characterized by difficulties with sleep maintenance.
Company: BioSpecifics Technologies Corp.
Treatment for: Dupuytren’s Disease
Xiaflex (collagenase clostridium histolyticum) is a collagenase product in development for the treatment of Dupuytren’s disease.